Moderna Therapeutics seeks $500M for IPO
If successful, it would be the largest-ever initial public offering for a biotech company. The company raised $500 million in a Series G round in February.
If successful, it would be the largest-ever initial public offering for a biotech company. The company raised $500 million in a Series G round in February.
The company, developing a reversal agent for an antiplatelet therapy in-licensed from AstraZeneca, had proposed an IPO at $12-14 per share.
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
The filing comes one week after the company, founded earlier this year with a $300 million Series A round by two former Kite executives, raised $120 million in a private financing.
The company, which has already raised more than $500 million in venture capital funding, would trade on the NASDAQ under the ticker symbol "GH."